You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 8, August 27, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Arrhythmias
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Medications That Prolong the QT Interval

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We wish to raise some methodological concerns about the article by Dr Al-Khatib and colleagues.1

Although the authors described a MEDLINE search, they did not provide a critical summary of published reports of drugs affecting the QT interval. Similarly, they did not include information from pharmacovigilance or postmarketing databases. Rather, their main table of results is based on an opinion survey whose methods and results were not presented.

Thus, we believe that several of their conclusions are unwarranted. For instance, the authors categorize sertraline's "potential . . . for causing QT prolongation" as "possible in high-risk patients." Yet there are no published data documenting that sertraline treatment is associated with QT prolongation or torsades de pointes in any high-risk patient population. Furthermore, in a double-blind, placebo-controlled clinical trial, Glassman et al2 reported that sertraline was not associated with a risk of QT prolongation or torsades de pointes . . . [Full Text of this Article]

John A. Gillespie, MD; Cathryn M. Clary, MD
Pfizer Inc
New York, NY



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Medications That Prolong the QT Interval
Mori J. Krantz, Bridget A. Martell, Julia H. Arnsten, and Marc N. Gourevitch
JAMA. 2003;290(8):1025.
EXTRACT | FULL TEXT  

Medications That Prolong the QT Interval
Carol Cappuccio
JAMA. 2003;290(8):1026.
EXTRACT | FULL TEXT  

Medications That Prolong the QT Interval—Reply
Sana M. Al-Khatib, Nancy M. Allen LaPointe, Judith M. Kramer, and Robert M. Califf
JAMA. 2003;290(8):1026.
EXTRACT | FULL TEXT  

What Clinicians Should Know About the QT Interval
Sana M. Al-Khatib, Nancy M. Allen LaPointe, Judith M. Kramer, and Robert M. Califf
JAMA. 2003;289(16):2120-2127.
ABSTRACT | FULL TEXT  

Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina
Alexander H. Glassman, Christopher M. O'Connor, Robert M. Califf, Karl Swedberg, Peter Schwartz, J. Thomas Bigger, Jr, K. Ranga Rama Krishnan, Louis T. van Zyl, J. Robert Swenson, Mitchell S. Finkel, Charles Landau, Peter A. Shapiro, Carl J. Pepine, Jack Mardekian, Wilma M. Harrison, and for the Sertraline Antidepressant Heart Attack Randomized Trial Group
JAMA. 2002;288(6):701-709.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.